Completed PHASE3 INTERVENTIONAL 2-arm NCT01622075

A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting Stent (PEPCAD)

A Multicenter, Randomized, Active Controlled Clinical Study to Evaluate the Safety and Efficacy of the Treatment of In-stent Restenosis Lesion by Paclitaxel-eluting PTCA- Balloon Catheter Versus Paclitaxel-eluting Stent

Sponsor: B. Braun Medical International Trading Company Ltd.

Conditions Coronary Instent Restenosis

Interventions SeQuent® Please Taxus Liberte

Updated 5 times since 2017 Last updated: Jul 22, 2015 Started: Mar 31, 2011 Primary completion: Apr 30, 2013 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01622075, this PHASE3 trial focuses on Coronary Instent Restenosis and remains completed. Sponsored by B. Braun Medical International Trading Company Ltd., it has been updated 5 times since 2011, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

B. Braun Medical International Trading Company Ltd.

Data source: B. Braun Medical International Trading Company Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China